Welcome to our dedicated page for Biodexa Pharmaceuticals news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals stock.
Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Biodexa Pharmaceuticals (BDRX) reported unaudited interim results for the six months ended June 30, 2026, highlighting pipeline progress, higher R&D spend and reduced administrative costs.
R&D costs rose 75% to £2.92m (1H25: £1.67m), driven by the Phase 3 Serenta trial of eRapa in FAP and manufacturing for newly in-licensed MTX240. R&D represented 63% of operating costs. Administrative costs fell 27% to £1.74m, mainly due to favourable FX movements. Net loss was £1.84m (1H25: £3.81m). Net cash used in operating activities increased to £4.61m, and total cash decreased by £5.31m to £3.23m at June 30, 2026.
Operationally, the company in-licensed MTX240 from Otsuka, expanded the eRapa Serenta Phase 3 trial (92 of 168 subjects enrolled to date, including planned Canadian sites), advanced investigator-initiated trials in NMIBC and T1D, and raised $3.5m gross on July 1, 2026 via a registered direct offering, warrant inducement and PIPE.
Biodexa (Nasdaq: BDRX) reported a key recruitment milestone in its registrational Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. As of August 19, 2026, 87 of a planned 168 subjects have been enrolled, exceeding the halfway target.
The double-blind, placebo-controlled study is planned to randomize patients 2:1 (drug:placebo) and is recruiting at 29 clinical sites across the US and five European countries, with three Canadian sites expected to open. Biodexa plans a futility analysis after 25 Progression Free Survival (PFS) events and database lock after 75 PFS events, using a composite endpoint to define PFS events.
The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas. eRapa, an oral mTOR inhibitor formulation of rapamycin, holds Orphan Drug Designation in the US and Europe for FAP.
Biodexa Pharmaceuticals (Nasdaq: BDRX) reported that all four resolutions at its July 29, 2026 General Meeting were passed. Resolutions 1 and 4 reduce the number of ordinary shares by a factor of 10,000 while keeping the nominal value at £0.000001 per share.
From July 30, 2026, the ordinary share per ADS ratio changes by 10,000, from 500,000:1 to 50:1, with the share reorganization effective at 08:00 BST (03:00 EDT. Biodexa said this is not a reverse split and proportional ownership is unchanged except for fractional entitlements. After the reorganization, 51,453,281 ordinary shares will be outstanding, equivalent to 1,029,063 ADSs, the same ADS total as before. Resolutions 2 and 3 authorize directors to allot shares on a non-pre-emptive basis.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has initiated new support activities for Familial Adenomatous Polyposis (FAP) patients and prescribers in France, holding its first round table meeting in Paris to facilitate experience-sharing among patients, advocacy groups and clinicians and to inform its goal of improving outcomes and quality of life.
These initiatives build on Biodexa’s global Early Access Program and Named Patient prescribing, which allow clinicians to prescribe its investigational mTOR inhibitor eRapa for FAP outside clinical trials. eRapa has US Orphan Designation, with plans to seek similar status in Europe, and is being advanced into a double‑blind, placebo‑controlled Phase 3 registrational trial in FAP, targeting 30 clinical sites in the US and Europe and 168 patients randomized 2:1. The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Biodexa Pharmaceuticals (Nasdaq: BDRX)/b) announced voting outcomes from its re-scheduled Annual General Meeting held on June 30, 2026.Ordinary resolutions 1–7 passed with majorities between 73% and 94%. Ordinary resolution 8, special resolution 10, and contingent resolution 11 did not pass.
Biodexa Pharmaceuticals (Nasdaq: BDRX) priced equity financings totaling approximately $3.5 million, including a registered direct offering, a concurrent private placement of pre-funded warrants, and a warrant inducement transaction.
The offerings, at an exercise/offer price of $2.85 per ADS, are expected to close around July 1, 2026, with net proceeds intended for development programs, working capital and general corporate purposes.
Biodexa (Nasdaq: BDRX) received approval from Health Canada to expand its registrational Serenta Phase 3 trial in familial adenomatous polyposis (FAP) into Canada.
The study is recruiting in 29 centers across the US and Europe, with Canada expected to add 3–4 sites. Serenta plans to enroll 168 patients; 73 are enrolled to date.
Biodexa Pharmaceuticals (Nasdaq: BDRX), a clinical-stage biopharmaceutical company focused on gastrointestinal cancers, adjourned its Annual General Meeting on June 17, 2026 due to lack of quorum.
The AGM is re-scheduled for 11:00am BST on June 30, 2026 at the company’s Cardiff offices, and previously submitted proxies remain valid.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has issued a shareholder letter outlining proposals to reorganize its share capital at the June 17, 2026 AGM.
The plan includes a 10,000:1 reverse split of 373,056,808,922 ordinary shares into 37,305,681, creation of E deferred shares, and changing the ordinary share/ADS ratio from 500,000:1 to 50:1, keeping approximately 746,113 ADSs and shareholder rights and ownership percentages unchanged.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced a partnership with Syngene to manufacture GMP clinical trial supplies of MTX240, covering both the active pharmaceutical ingredient and dosage form.
According to the company, Syngene previously manufactured tolimidone on time and on budget and, following Biodexa's MTX240 license from Otsuka in early February, designed a GMP program within a few weeks.